Skip to content
Open in App
Recordati logo

Recordati

web2

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches,...

Symbol · 0KBS
Company profile

About

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

People

Company team

KS

Kim Stratton

Non-Executive Director

Company leadership profile.

DM

Diva Moriani

Lead Independent Director

Company leadership profile.

AR

Andrea Recordati

Non-Executive Chairman

Company leadership profile.

RK

Robert Koremans

CEO & Director

Company leadership profile.

CP

Cathrin Petty

Executive Director

Company leadership profile.

GM

Giampiero Mazza

Executive Director

Company leadership profile.

JS

Joanna Susan Le Couilliard

Independent Non-Executive Director

Company leadership profile.

MA

Myriam Amato

Chair of Board of Statutory Auditors

Company leadership profile.

LF

Luigi Felice La Corte

Director

Company leadership profile.

PP

Piergiorgio Peluso

Independent Non-Executive Director

Company leadership profile.

SS

Stephen Sands

Independent Director

Company leadership profile.

EM

Ezio Maria Simonelli

Statutory Auditor

Company leadership profile.

LF

Lucia Foti Belligambi

Member of Board of Statutory Auditor

Company leadership profile.

SP

Sandro Piazza

Member of Supervisory Body

Company leadership profile.

Expert coverage

1 expert evaluated Recordati.

Orbitrum research

Experts evaluating Recordati

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment